Core Viewpoint - China National Pharmaceutical Group Co., Ltd. has received approval from the China Securities Regulatory Commission to publicly issue corporate bonds to professional investors, with a total face value not exceeding 2 billion yuan [1]. Group 1 - The company held its annual general meeting on May 16, 2025, where it approved the proposal for the registration of corporate bonds and short-term financing bills [1]. - The approval from the regulatory authority allows the company to issue bonds within 24 months from the date of approval [1]. - The company plans to implement the bond issuance based on the authorization from the annual general meeting and will fulfill its information disclosure obligations in a timely manner [1].

Core Viewpoint - China Medical (600056.SH) has received approval from the China Securities Regulatory Commission to publicly issue corporate bonds with a total face value of up to 2 billion yuan to professional investors [1] Group 1 - The approval is documented in the regulatory notice (Zheng Jian Xu Ke [2026] No. 21) [1] - The company can issue the bonds within 24 months from the date of approval [1] - The issuance can be conducted in multiple tranches during the validity period of the registration [1]

Core Viewpoint - China Medical (600056.SH) has received approval from the China Securities Regulatory Commission to publicly issue corporate bonds with a total face value of up to 2 billion yuan to professional investors [1] Group 1 - The approval allows the company to issue bonds within a validity period of 24 months from the date of registration [1] - The company can issue the bonds in multiple tranches during the registration validity period [1]

证券代码：600056 证券简称：中国医药 公告编号：临 2026-004 号 中国医药健康产业股份有限公司 关于向专业投资者公开发行公司债券 获得注册批复的公告 中国医药健康产业股份有限公司(以下简称"公司")于 2025 年 5 月 16 日召 开 2024 年年度股东大会，审议并通过了《关于开展公司债和超短期融资券注册 的议案》。近日，公司收到中国证券监督管理委员会《关于同意中国医药健康产 业股份有限公司向专业投资者公开发行公司债券注册的批复》（证监许可〔2026〕 21 号）。据此批复，公司可以向专业投资者公开发行面值总额不超过 20 亿元公 司债券。此批复自同意注册之日起 24 个月内有效，公司在注册有效期内可以分 期发行。 按照有关法律法规和上述批复的要求，公司董事会及经营层将根据公司 2024 年年度股东大会的授权范围内择机实施上述公司债券发行相关工作，并及 时履行信息披露义务。 特此公告。 中国医药健康产业股份有限公司董事会 2026 年 1 月 13 日 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 ...

Core Viewpoint - China Medical (600056.SH) has received approval from the China Securities Regulatory Commission to publicly issue corporate bonds totaling up to 2 billion yuan to professional investors [1] Group 1 - The company will hold its 2024 annual shareholders' meeting on May 16, 2025, to review and approve the proposal for the issuance of corporate bonds and ultra-short-term financing bills [1] - The approval from the regulatory authority allows the company to issue bonds within a validity period of 24 months from the date of registration [1] - The total face value of the corporate bonds that can be issued is capped at 2 billion yuan [1]

Core Viewpoint - China National Pharmaceutical Group (600056.SH) has announced the approval to issue corporate bonds totaling up to 2 billion yuan to professional investors, enhancing its financial flexibility for future projects [1] Group 1: Corporate Actions - The company will hold its 2024 annual shareholders' meeting on May 16, 2025, to review and approve the proposal for the issuance of corporate bonds and short-term financing bills [1] - The China Securities Regulatory Commission has granted approval for the company to publicly issue corporate bonds with a total face value not exceeding 2 billion yuan [1] - The approval is valid for 24 months from the date of registration, allowing the company to issue the bonds in multiple tranches within this period [1]

Core Viewpoint - The company has received approval from the China Securities Regulatory Commission to publicly issue corporate bonds totaling up to 2 billion yuan to professional investors [1] Group 1 - The company held its annual shareholder meeting in 2024, where it approved a proposal to register for corporate bonds and ultra-short-term financing bills [1] - The approval from the regulatory body allows the company to issue bonds with a total face value not exceeding 2 billion yuan, valid for 24 months from the date of approval [1] - The company has the option to issue the bonds in multiple tranches within the validity period of the registration [1]

Market Performance - The pharmaceutical commercial sector increased by 0.8% on January 12, with RunDa Medical leading the gains [1] - The Shanghai Composite Index closed at 4165.29, up 1.09%, while the Shenzhen Component Index closed at 14366.91, up 1.75% [1] Top Gainers - RunDa Medical (603108) closed at 19.47, up 8.53%, with a trading volume of 1.0956 million shares and a transaction value of 2.123 billion [1] - Jia Shi Tang (002462) closed at 17.13, up 6.33%, with a trading volume of 441,200 shares and a transaction value of 733 million [1] - Yao Yi Gou (300937) closed at 38.42, up 4.54%, with a trading volume of 127,500 shares and a transaction value of 480 million [1] Top Losers - Nanjing Pharmaceutical (600713) closed at 5.43, down 1.63%, with a trading volume of 284,200 shares and a transaction value of 154 million [2] - Zhong Yao Holdings (000950) closed at 6.24, down 1.11%, with a trading volume of 740,900 shares and a transaction value of 461 million [2] - Ying Te Group (000411) closed at 12.81, down 1.08%, with a trading volume of 187,000 shares and a transaction value of 239 million [2] Capital Flow - The pharmaceutical commercial sector experienced a net outflow of 234 million from institutional investors and 184 million from speculative funds, while retail investors saw a net inflow of 417 million [2] - RunDa Medical had a net inflow of 123 million from institutional investors, but a net outflow of 171 million from speculative funds [3] - Jia Shi Tang experienced a net inflow of 80.845 million from institutional investors, with a net outflow of 28.7836 million from speculative funds [3]

Market Performance - The pharmaceutical commercial sector increased by 1.32% on January 9, with RunDa Medical leading the gains [1] - The Shanghai Composite Index closed at 4120.43, up 0.92%, while the Shenzhen Component Index closed at 14120.15, up 1.15% [1] Top Gainers - RunDa Medical (603108) closed at 17.94, up 9.99% with a trading volume of 846,200 shares [1] - Huaren Health (301408) closed at 22.17, up 9.97% with a trading volume of 627,800 shares [1] - Shangyu Pingmin (301017) closed at 17.24, up 7.75% with a trading volume of 336,500 shares [1] Other Notable Stocks - Zhongyao Holdings (000950) closed at 6.31, up 5.87% with a trading volume of 1,147,000 shares [1] - Saily Medical (603716) closed at 27.83, up 4.39% with a trading volume of 783,100 shares [1] Market Capital Flow - The pharmaceutical commercial sector experienced a net outflow of 122 million yuan from institutional investors and 174 million yuan from speculative funds, while retail investors saw a net inflow of 296 million yuan [2] - The trading volume and turnover for various stocks indicate a mixed sentiment among different investor categories [2] Individual Stock Fund Flow - RunDa Medical had a net inflow of 2.30 billion yuan from institutional investors, while it faced a net outflow of 1.36 billion yuan from speculative funds [3] - Zhongyao Holdings saw a net inflow of 61.04 million yuan from institutional investors, with a net outflow of 62.93 million yuan from retail investors [3] - The overall fund flow indicates varying levels of confidence among different investor types in the pharmaceutical sector [3]

Core Viewpoint - China Medical announced that its wholly-owned subsidiary, Hainan Tongyong Sanyang Pharmaceutical Co., Ltd., has received the drug registration certificate for Nicergoline tablets from the National Medical Products Administration [2] Group 1 - The approval of Nicergoline tablets marks a significant regulatory milestone for the company [2] - This development may enhance the company's product portfolio and market competitiveness in the pharmaceutical industry [2]